EP Patent

EP4056179A1 — Dosing regimen for ponesimod, a selective s1p1 receptor agonist

Assigned to Laboratoires Juvise Pharmaceuticals SAS · Expires 2022-09-14 · 4y expired

What this patent protects

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

USPTO Abstract

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.

Drugs covered by this patent

Patent Metadata

Patent number
EP4056179A1
Jurisdiction
EP
Classification
—
Expires
2022-09-14
Drug substance claim
No
Drug product claim
No
Assignee
Laboratoires Juvise Pharmaceuticals SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.